Glomerular diseases encompass a diverse group of kidney disorders characterized by damage to the glomeruli, the tiny filters within the kidneys. Include rare forms such as Alport syndrome, membranous nephropathy, and focal segmental glomerulosclerosis. Our company, as a leading research services provider with deep expertise, is committed to advancing research and supporting the development of innovative therapies to tackle the complexities of glomerular diseases.
Introduction to Glomerular Diseases
Glomerular diseases, characterized by damage to the glomeruli in the kidneys, represent a significant global health concern due to their increasing prevalence. Affecting approximately 0.5% to 1% of the global population, these diseases can lead to chronic kidney failure if not properly managed. Recent advancements in research have shed light on the complex pathophysiology underlying various glomerular disorders, emphasizing the need for novel therapeutic strategies.
Pathogenesis of Glomerular Diseases
Recent studies have illuminated the complex pathogenesis of glomerular diseases, which involves a multifaceted interplay of genetic, immunological, and environmental factors. Immune-mediated injury to the glomerular capillary walls is central to many of these disorders, often triggered by autoantibodies or circulating immune complexes. Advances in molecular biology have also revealed significant roles for specific genetic mutations and epigenetic modifications, which contribute to disease susceptibility and progression.
Fig.1 Pathogenesis of minimal change disease. (Mansour, I., et al., 2023)
Therapeutics Development for Glomerular Diseases
In advancing therapeutics for glomerular diseases, the emphasis is on integrating groundbreaking modalities such as Small molecule drugs and therapeutic antibody, setting a new direction for effective treatment strategies.
Table.1 Summary of ongoing clinical trials for drugs targeting the GFB. (Daehn, I. S., and J. S. Duffield., 2021)
| Drug |
Study population |
Target |
Type of molecule |
Status |
NCT identifier |
| Bardoxolone methyl |
Alport syndrome |
NRF2 |
Small molecule |
Phase II/III |
NCT03019185 |
| Lademirsen |
Alport syndrome |
miR-21 |
Antisense oligonucleotide |
Phase II |
NCT02855268 |
| VAR-200 |
FSGS |
Cholesterol efflux |
Small molecule |
Phase I |
|
| Antibody |
FSGS |
suPAR |
Neutralizing antibody |
Preclinical |
NCT03448692 |
| PF-06730512 |
FSGS |
ROBO2 |
Fc fusion protein |
Phase II |
|
| siRNA |
Pre-eclampsia |
sFLT1 |
siRNA |
Late preclinical |
|
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At our company, we are proud to offer a comprehensive range of services to support our clients in developing innovative therapies for glomerular diseases. Our team of skilled scientists, nephrologists, and immunologists utilizes advanced technologies and deep industry expertise to accelerate the advancement of your therapeutic projects.
Therapeutic Development
Diseases Model Development
- Cell-based Models
- Genetically Engineering Model
- Induced Disease Model
- Humanized Animal Model
- Syngeneic Model
- Xenograft Model
Types of Glomerular Diseases
Glomerular diseases comprise a diverse group of complex renal disorders, each with unique genetic and pathological characteristics. Understanding the various types of glomerular diseases is crucial for devising effective treatment strategies.
| A-F |
F-M |
N-W |
- Autosomal Dominant Steroid-Resistant Nephrotic Syndrome
- Autosomal Recessive Steroid-Resistant Nephrotic Syndrome
- Benign Familial Haematuria
- Denys-Drash Syndrome
- Fabry's Disease
- Familial Amyloidosis
- Familial Hypertension
- Fechtner's Syndrome
|
- Focal Segmental Glomerulosclerosis (FSGS)
- Glomerular Diseases
- Hypokalemia
- Hypomagnesemia
- Immunoglobulin A Nephropathy (IgAN)
- Membranous Nephropathy
- Mitochondrial Disorders with Steroid-Resistant Nephrotic Syndrome
|
- Nail-patella syndrome
- Pierson's syndrome
- Schimke immuno-osseous dystrophy
- Wilms' Tumour, Aniridia, Genitourinary Anomalies, Retardation Syndrome (WAGR Syndrome
|
Our company is dedicated to offering complete, one-stop preclinical development services, covering all aspects from disease model creation to cutting-edge therapeutic research. Additionally, we provide comprehensive pharmacokinetics and drug safety evaluation services to ensure rigorous assessment and support for successful drug development.
If you are interested in our services, please don't hesitate to
contact us.
References
- Mansour, I., et al. "Contemporary Monoclonal Antibody Utilization in Glomerular Diseases." Mayo Clin Proc Innov Qual Outcomes 7.4 (2023): 276-90.
- Selvaskandan, H., I. Pawluczyk, and J. Barratt. "Clinical Application of Micrornas in Glomerular Diseases." Nephrol Dial Transplant 38.6 (2023): 1375-84.
- Daehn, I. S., and J. S. Duffield. "The Glomerular Filtration Barrier: A Structural Target for Novel Kidney Therapies." Nat Rev Drug Discov 20.10 (2021): 770-88.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
